Pacritinib Clinical Trials
13 recruitingDrug
Phase 210Phase 14Phase 31
Showing 1–13 of 13 trials
Recruiting
Phase 2
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618
Recruiting
Phase 2
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
VEXAS SyndromeVEXAS
Swedish Orphan Biovitrum78 enrolled39 locationsNCT06782373
Recruiting
Phase 1
Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
City of Hope Medical Center10 enrolled1 locationNCT06675123
Recruiting
Phase 1Phase 2
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Graft vs Host Disease
National Cancer Institute (NCI)50 enrolled2 locationsNCT05531786
Recruiting
Phase 2
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+6 more
University of Washington25 enrolled1 locationNCT04282187
Recruiting
Phase 2
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
Leukemia, Myelomonocytic, Chronic
Theradex66 enrolled4 locationsNCT07033598
Recruiting
Phase 2
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative Neoplasm
University of Washington27 enrolled1 locationNCT07148947
Recruiting
Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting
Phase 2
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
MyelofibrosisModerate ThrombocytopeniaMild Thrombocytopenia
Karyopharm Therapeutics Inc58 enrolled70 locationsNCT05980806
Recruiting
Phase 2
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Lymphoproliferative DisordersT-Cell Neoplasm
University of Michigan Rogel Cancer Center100 enrolled6 locationsNCT04858256
Recruiting
Phase 2
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Lymphoplasmacytic LymphomaWaldenström MacroglobulinemiaB-Cell Lymphoproliferative Disorder+1 more
Shayna Sarosiek, MD30 enrolled1 locationNCT06986174
Recruiting
Phase 1Phase 2
Pacritinib in CMML
Chronic Myelomonocytic Leukemia
Douglas Tremblay26 enrolled1 locationNCT06159491
Recruiting
Phase 1
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
VEXASE1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic Syndrome
Washington University School of Medicine15 enrolled1 locationNCT06538181